PR Newswire - 09 Mar 2025
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR® ...
Roche - 02 Mar 2025
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies ...